Fulgent Genetics/$FLGT
1D1W1MYTD1Y5YMAX
Capital at risk
About Fulgent Genetics
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
- Ticker
- $FLGT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,315
- Headquarters
- El Monte, United States
- Website
- www.fulgentgenetics.com
Fulgent Genetics Metrics
BasicAdvanced
$556M
-
-$2.81
0.89
-
Price and volume
Market cap
$556M
Beta
0.89
52-week high
$31.04
52-week low
$13.46
Average daily volume
302K
Financial strength
Current ratio
6.338
Quick ratio
4.565
Long term debt to equity
0.711
Total debt to equity
0.964
Interest coverage (TTM)
-960.73%
Profitability
EBITDA (TTM)
-89.461
Gross margin (TTM)
35.58%
Net profit margin (TTM)
-26.05%
Operating margin (TTM)
-35.59%
Effective tax rate (TTM)
7.55%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-6.30%
Return on equity (TTM)
-8.11%
Valuation
Price to revenue (TTM)
1.88
Price to book
0.55
Price to tangible book (TTM)
0.7
Price to free cash flow (TTM)
-5.868
Free cash flow yield (TTM)
-17.04%
Free cash flow per share (TTM)
-3.442
Growth
Revenue change (TTM)
6.83%
Earnings per share change (TTM)
68.55%
3-year revenue growth (CAGR)
1.76%
10-year revenue growth (CAGR)
37.70%
3-year earnings per share growth (CAGR)
19.66%
10-year earnings per share growth (CAGR)
17.72%
What the Analysts think about Fulgent Genetics
Analyst ratings (Buy, Hold, Sell) for Fulgent Genetics stock.
Analyst projections of the future price of Fulgent Genetics stock.
Bulls say / Bears say
Therapeutic pipeline delivered strong Phase 2 clinical results at ASCO 2026 for FID-007 in head and neck cancer, with objective response rate of 61.9% and median progression-free survival of 6.7 months, positioning the candidate for a planned Phase 3 trial (Business Wire)
Completed acquisition of Bako Diagnostics and StrataDx for $56.9 million in March 2026, diversifying its laboratory services into specialty and dermatopathology testing to expand its addressable market (Business Wire)
Reported sequential Q2 2026 revenue growth of 20.1% to $85.4 million, demonstrating resilience and momentum following first-half headwinds (Yahoo Finance)
Precision Diagnostics revenue declined 5% sequentially in Q4 2025 due to its largest customer bringing testing in-house, underscoring customer concentration risk (LSEG)
GAAP net loss widened to $29.5 million in Q2 2026, reflecting persistent challenges in achieving profitability despite revenue gains (Yahoo Finance)
Non-GAAP loss of $16.2 million, or $0.58 per share, in Q2 2026 highlights continuing operational cash burn and difficulty offsetting costs with revenue growth (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 27 Aug 2026.
Fulgent Genetics Financial Performance
Revenues and expenses
Fulgent Genetics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Fulgent Genetics News
AllArticlesVideos
Funds containing Fulgent Genetics
Fund name | Fund size | $FLGT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.